About MBX Biosciences
MBX Biosciences is a company based in Carmel (United States) founded in 2018. MBX Biosciences has raised $215.6 million across 4 funding rounds from investors including Orbimed, RA Capital and Driehaus. The company has 43 employees as of December 31, 2024. MBX Biosciences offers products and services including Canvuparatide, MBX 1416, MBX 4291, and MBX 2109. MBX Biosciences operates in a competitive market with competitors including Neurocrine, Crinetics, Zucara Therapeutics, Amolyt Pharma and OMass Therapeutics, among others.
- Headquarter Carmel, United States
- Employees 43 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Mbx Biosciences, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$61.92 M (USD)-90.16as on Dec 31, 2024
-
EBITDA
-$67.95 M (USD)-93.29as on Dec 31, 2024
-
Total Equity Funding
$215.6 M (USD)
in 4 rounds
-
Latest Funding Round
$63.5 M (USD), Series C
Aug 05, 2024
-
Investors
Orbimed
& 10 more
-
Employee Count
43
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of MBX Biosciences
MBX Biosciences is a publicly listed company on the NASDAQ with ticker symbol MBX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of MBX Biosciences
MBX Biosciences offers a comprehensive portfolio of products and services, including Canvuparatide, MBX 1416, MBX 4291, and MBX 2109.
Peptide therapy for treating endocrine disorders effectively.
Advanced treatment for metabolic conditions and related issues.
Peptide-based solution for endocrine and health management.
Innovative peptide for addressing metabolic disorders.
People of MBX Biosciences
Unlock access to complete
Leadership Team
12 people
Product Management Team
3 people
Finance and Accounting
2 people
Data Analysis and Operations Team
1 people
Operations Team
1 people
Software Development Team
1 people
Accountant Team
1 people
Human Resources and Administration
1 people
Unlock access to complete
Funding Insights of MBX Biosciences
MBX Biosciences has successfully raised a total of $215.6M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $63.5 million completed in August 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in MBX Biosciences
MBX Biosciences has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, RA Capital and Driehaus.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Deep Track Capital is engaged in biotechnology investment activities.
|
Locked | Locked | Locked | |
|
Healthcare investment firm focused on novel therapeutics development.
|
Locked | Locked | Locked | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked |
Investor details for MBX Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by MBX Biosciences
Investment portfolio details for MBX Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - MBX Biosciences
Detailed financials for MBX Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Mbx Biosciences Comparisons
Peer comparison for MBX Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of MBX Biosciences
MBX Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Neurocrine, Crinetics, Zucara Therapeutics, Amolyt Pharma and OMass Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Developer of therapies for the treatment of endocrine-related diseases and cancers
|
|
| Locked | Locked | Locked |
Developing a long-term therapeutic approach to prevent hypoglycemia in patients with diabetes
|
|
| Locked | Locked | Locked |
Peptide therapeutics are developed for rare endocrine and metabolic disorders.
|
|
| Locked | Locked | Locked |
Proprietary mass spectrometry technologies are developed for protein assembly analysis.
|
Detailed competitors of MBX Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Mbx Biosciences
Complete news archive for MBX Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MBX Biosciences
MBX Biosciences was founded in 2018 and raised its 1st funding round 1 year after it was founded.
MBX Biosciences is headquartered in Carmel, United States. It is registered at Carmel, California, United States.
MBX Biosciences is a funded company, having raised a total of $215.6M across 4 funding rounds to date.
As of Dec 31, 2024, the latest employee count at MBX Biosciences is 43.
MBX Biosciences is a developer of drugs for the treatment of rare endocrine diseases. It has developed endocrine drugs including Forteo and Humalog for the treatment of rare diseases. It uses use peptide hormones to regulate many physiological functions including growth, energy utilization, metabolism, gastrointestinal function, and stress responses.
MBX Biosciences's top competitors include Crinetics, Neurocrine and Zucara Therapeutics.
MBX Biosciences offers Canvuparatide, MBX 1416, MBX 4291, and MBX 2109.
Yes, MBX Biosciences is publicly traded on NASDAQ under the ticker symbol MBX.
MBX Biosciences has 11 investors. Key investors include Orbimed, RA Capital, Driehaus, Norwest Venture Partners, and Frazier Healthcare Partners.
The ticker symbol of MBX Biosciences is MBX on NASDAQ.